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Since its discovery at the beginning of 20th century, Human African Trypanosomiasis or sleeping 
sickness has killed several hundred thousands of individuals in Africa, mainly in Central part of the 
continent. The actual situation of the disease in several countries is dramatic, such as in Sudan, 
Democratic Republic of Congo or Angola. However, diagnosis is still based on the detection of 
parasites in blood or lymphatic juice by microscopy, like in 1930's. Furthermore, since the discovery of 
melarsoprol in 1949, no novel drugs have been synthesized for treatment. This must consider it within 
the whole context of "most-neglected diseases" but some findings obtained through biotechnology are 
discussed in terms of epidemiology and control applications. 
 
Key words: Human African Trypanosomiasis, neglected disease, biotechnologies. 
 
 
Nowadays, sleeping sickness or Human African 
Trypanosomiasis (HAT) is considered to be one of “the 
most-neglected diseases”, in terms of drug development 
and continues to plague Africa (Morel, 2003). World 
Health Organization estimates that about 600,000 
persons are currently infected, most of them in Central 
Africa. The chronic form of HAT is a lethal disease 
caused by a parasite named Trypanosoma brucei 
gambiense. This parasite is transmitted by vector, tsetse 
flies, most of which belong to the species Glossina 
palpalis. Since the discovery of this pathology at the 
beginning of 20th century (e.g. Bruce and Nabarro, 1903), 
HAT has killed several hundred thousands of individuals 
in Africa, mainly in Central part of the continent (Martin et 
al., 1909; W.H.O., 1998). Although the epidemic of 1920-
1930’s was successfully controlled  thanks  to  Dr.  Jamot  
 




and mobile medical teams surveys, especially in 
Cameroon between 1928 and 1930, the actual situation 
of the disease in several countries is dramatic, such as in 
Sudan, Democratic Republic of Congo or Angola. Many 
research teams have tried to improve our knowledge of 
the epidemiology, pathogenicity and genetics of HAT for 
about 40 years, using sophisticated tools for diagnosis, 
isolation and characterization of trypanosomes. However, 
the absence of operational therapeutic alternatives 
appears to be in contradiction with all the research 
activities mentioned above (this list is not exhaustive 
unfortunately). Thus, although biotechnologies are useful, 
for example, to confirm different pathogenic forms of HAT 
(genetic distinction between T. b. gambiense and T. b. 
rhodesiense, the agent of acute form of the disease), the 
existence of an animal reservoir, the identification of 
infected flies, most of the current knowledge on the 
epidemiology of HAT was known 70 years ago (see 
Mulligan, 1970). Moreover, diagnosis is still based on the 
detection of parasites in blood or lymphatic juice by 
microscopy, as during the time of Dr. Jamot in 1930’s. 
Indeed, about 70 years ago, HAT specialists already 
knew that a chronic form occurred in West and Central 
Africa while an acute form was spreading in East Africa. 
Even the main drug used by Dr. Jamot, Tryparsamide, 
was chemically an arsenic derivative, like melarsoprol, 
discovered by Friedheim in 1949 (see Dumas et al., 
1999). Since then, few novel drugs have synthesized, 
mostly chance discoveries of compounds initially 
intended to treat cancer, Ornidyl (Dl-
difluoromethylornithine) or Chagas disease, Lampit 
(nifurtimox). Both of these drugs are used for the 
treatment of second stage of HAT or after treatment 
failure when using melarsoprol (see the review by Van 
Nieuwenhove, 1999). 
This is reality, but we must consider it within the whole 
context of “most-neglected diseases” and discuss some 
findings obtained through biotechnology. A review on this 
subject has been published by Dumas and colleagues 
(1999). Drugs and therapy will not be discussed because 
since the introduction of Atoxyl in 1904, the ideal 
antitrypanosomal drug, which is cheap, effective in early 
and advanced sleeping sickness, of low toxicity, with a 
long duration of action after oral absorption and not 
rapidly inducing resistance, has yet to be discovered 
(Van Nieuwenhove, 1999). While some new diamidines 
(e.g. DB 289, Brun, personal communication), and 
combination therapy are under study, none of these is yet 
operational for treatment. Two issues of research will be 
discussed: first concerning mass screening, diagnostic 
and stage determination of patients, second about the 
epidemiology of the disease (e.g. isolation, biology and 
genetic of trypanosomes). 
In 1978, the Card Agglutination Test for 
Trypanosomiasis (CATT/T. b. gambiense; Magnus et al., 





observed due to the presence of anti-trypanosome 
antibodies in blood. Therefore, CATT/T. b. gambiense 
allowed mass screening, but parasite detection was 
required in blood or lymph node aspirate. Today, the 
CATT/T. b. gambiense is the usual test for mass 
screening, but its specificity is low because false positive 
results caused by others pathologies such as malaria. 
CATT/T. b. gambiense is still being evaluated despite 
many previous studies and simplification of this test or 
alternative version such as a version using Latex 
monoclonal antibodies or a micro-method using filter 
paper for blood collection named micro-CATT (e.g. 
Jamonneau et al., 2000c; Truc et al., 2002a). Again, 
considering the lack of new drugs and despite 
improvement of diagnosis tools for many other diseases, 
HAT/T. b. gambiense diagnosis is still based on parasite 
detection like in 1930’s.  
The use of the anion exchange cellulose 
chromatography was a major finding for studying 
trypanosomes (Lanham and Godfrey, 1970). Indeed, the 
low number of bloodstreams forms (BSF) (T. b. 
gambiense) and their low virulence when inoculated to 
rodents were limiting factors for biological and genetic 
studies. Although chromatography was used for 
concentration of trypanosomes from blood, it has been 
adapted for diagnosis in the field (miniature anion-
exchange centrifugation technique, mAECT; Lumsden et 
al., 1979). The mAECT is used in several countries. 
Before 1979, the traditional techniques for microscopic 
examination of blood for trypanosomes detection were 
based on thin, wet or thick blood films with a sensitivity of 
33-17 trypanosomes per ml of blood, while mAECT 
detected 3-4 trypanosomes per ml of blood. An individual 
is declared infected by sleeping sickness when parasite 
is detected either in blood or lymph node aspirate (WHO, 
1998). Thus, a better detection of parasites using mAECT 
was a major improvement for control activities. Other 
concentration techniques were proposed, such as 
Capillary Tube Centrifugation technique or CTC (Woo, 
1970), the Quantitative Buffy Coat or QBC (Bailey and 
Smith, 1992) but, unfortunately, some national control 
programs in Africa can only perform microscopic 
examination of thick or wet blood films for financial 
reasons and/or lack of appropriated equipment. Again, 
discordance exists, unfortunately, between biotechnology 
and techniques used for control activities. This could 
partially explain why HAT is considered to be one of the 
“most-neglected diseases”. 
Following the infective bite by tsetse fly, the classical 
clinical evolution of HAT in human starts with the 
haemato-lymphatic or first stage (P1), characterized by 
only few typical clinical signs (primary lesion or chancre, 
swollen lymph node or Winterbottom’s sign). Then, the 
meningo-encephalitic or second stage (P2) occurs due to 
the presence of trypanosomes in the cerebrospinal fluid 






neurological disorders. The classical stage determination 
method is based on CSF cell counting (cut-off, 5 cells/µl), 
CSF protein concentration (cut-off, 37 mg/100ml by the 
dye-binding protein assay) and/or the presence of 
trypanosomes detected by simple or double 
centrifugation of CSF (WHO, 1998). However the cut-off 
values and the sensitivity of detection of trypanosomes in 
CSF remain doubtful (Truc et al., 1999). On the other 
hand, clinical examination for detection of neurological 
disorders may contribute to detect a second stage of the 
disease but is not satisfactory either (Bisser et al., 2000). 
However, the appropriate treatment depends on the 
accurate determination of disease stage. Indeed, for the 
chronic form caused by T. b. gambiense, the treatment of 
patients in stage P1 is pentamidine while melarsoprol is 
used for stage P2. Because of toxicity and severe, 
potentially fatal side effects of melarsoprol and the 
possibility to cure some P2 patients using pentamidine 
(Doua et al., 1996), stage determination must be highly 
accurate. Recently, new biological markers for parasite 
detection in the CSF have been discovered. For example, 
specific IgM antibodies (Latex/IgM: Lejon et al., 1998, 
2002, Büscher et al., 1999) and anti-galactocerebroside 
antibodies in CSF produced in response to the 
progressive demyelinating process triggered by the 
presence of trypanosomes in the cerebral environment 
(Bisser et al., 2000). However, these techniques and 
others such as parasite DNA detection in CSF by PCR 
based methods are not yet ready for a routine use. 
Indeed, PCR is yet unrealistic for a field use, and the cut-
off value for positive result of Latex/IgM is unknown. 
Therefore, stage determination is partially based on 
parasite detection in CSF, like in 1930’s. This confirms 
again the gap between un-appropriated tools for control 
activities and products of the new technologies. 
Isolation of BSF of T. b. gambiense is difficult in field 
conditions because of low parasitaemia in blood and low 
virulence of these parasites when inoculated in 
experimental rodents (see Gibson et al., 1999). However, 
BSF are required for different research purposes, such as 
studies on population genetic or identification of hosts. 
Thus, an adaptation and simplification of the procedure 
using anion-exchange centrifugation (Lanham & Godfrey, 
1970) was described (Truc et al., in press). The objective 
was to concentrate and freeze in field conditions a high 
number of BSF from patients. On the other hand, the 
isolation of procyclic forms of T. b. gambiense from 
mammals has been improved thanks to the KIVI (Kit for 
In Vitro Isolation of trypanosomes, Aerts et al., 1992). Its 
efficiency was demonstrated, both for T. b. gambiense 
from humans (Truc et al., 1992), T. brucei spp. and T. 
congolense from domestic and wild animals (Oka Komoin 
et al., 1994). However, its value as operational diagnostic 
test has been controversed (Mc Namara et al., 1995). 
Indeed, KIVI cannot be used as a tool for quick parasite 
detection in the field because of the  delay  for  culture  to  




become positive. Again, the mAECT remains the most 
useful technique for diagnostic of HAT, when available. 
The genetic identification of trypanosomes was 
performed first by Multi-Locus Enzyme Electrophoresis 
MLEE (Godfrey and Kilgour, 1976, Gibson et al., 1980). 
Restriction Fragment Length Polymorphism of kinetoplast 
DNA has been also used to distinguish stocks of T.b. 
gambiense from other sub-species (e.g. Borst et al., 
1980). For MLEE, several protocols were described, 
using either starch or acetate gel, studying a range of 
metabolic enzymes called isoenzymes (e.g. Gibson et al, 
1980, Truc et al., 1991). A recent short review has been 
published about molecular biology and identification of 
trypanosomes (Truc and Cuny, 2000). The ancestral 
taxonomy distinguished T. b. gambiense (agent of the 
chronic form in West and Central Africa), T. b. 
rhodesiense (agent of the acute form in East Africa) and 
T. b. brucei, agent of the “nagana” in cattle and 
pathogenic for others animals but non-infective for 
human. This classification was partially confirmed by 
genetic analysis. Indeed, isoenzyme results indicated that 
T. b. gambiense was almost homogeneous (group 1: 
Gibson, 1986) but some strains did not fit into this group 
1 and were suspected to be more pathogenic (Truc et al., 
1997). Furthermore, the pathogenicity of trypanosomes 
and their corresponding genetic identification did not 
confirm the existence of only a chronic form of HAT in 
West Africa (Jamonneau et al., 2000, a, b, 2002). While 
T. b. gambiense was clearly separated from T. b. 
rhodesiense, sub-groups were described within T. b. 
rhodesiense as specific of a given geographical location 
such as busoga group (see Gibson et al., 1999). On the 
other hand, genetic analysis indicated that T. b. brucei 
was closely related to T. b. rhodesiense. The hypothesis 
of a common ancestor for both T. b. rhodesiense and T. 
b. brucei was mentioned (see Gibson et al., 1999). But 
these findings did not change control against HAT, 
excepted in cases of overlap of T. b. gambiense and T. b. 
rhodesiense foci, such as in Uganda or Kenya. More 
sophisticated techniques, such as PCR based methods, 
confirmed isoenzyme findings with even more distinction 
within each sub-species (e.g. RAPD). Furthermore, the 
use of microsatellite markers allowed to evidence co-
infection by different genotypes in the same patient (Truc 
et al., 2002b). Consequences of co-infection may be 
important and justify in part the genotype selection 
detected by the isolation method (Jamonneau et al., 
2003). Hence, it should be a strong assumption that most 
of strains studied were only part of the real natural 
populations of trypanosomes infecting patients. Thus, a 
bias might be introduced in many studies for which 
parasite isolation and identification are required, such as 
genetic or drug sensitivity assays. New procedures must 
be set up to avoid isolation and selection of 
trypanosomes in vivo or in vitro in order to get reliable 
results    considering    the    natural    diversity    of    wild  
 




trypanosomes populations. For instance, trypanosomes 
in body fluids could be used to amplify particular genes of 
parasite DNA (such as a gene involved in resistance to 
drug). An alternative would be to induce cloning and 
reproduction of individual trypanosome freshly collected 
from patient, animal or tsetse fly. This is unrealistic at the 
moment for technical reasons but must be seriously 
investigated as soon as possible.  
Another interest of genetic identification of parasite was 
confirmation of the clonal mode of reproduction 
(Tibayrenc et al., 1990), propagation of HAT (Truc and 
Cuny, 2001), distribution in space and time (endemic or 
epidemic, Truc and Tibayrenc, 1993), suspicion of an 
animal reservoir of parasites (e.g. Gibson et al., 1978, 
1980; Mehlitz et al., 1982; Truc et al., 1991, 1997; Truc 
and Tibayrenc, 1993). Isoenzymes and other genetic 
markers indicated that trypanosomes circulating in 
animals are similar to those found in human. Thus 
domestic animals turn to be a putative animal reservoir of 
HAT. For this latter point, it is only a presumption because 
no evidence was given about an active role of the animal 
reservoir in transmission of HAT to human. Moreover, the 
role of the animal reservoir for the chronic form might be 
protective for the human population. Indeed, where 
animals are infected by T. b. gambiense, the prevalence 
in human population is low, as for example in Côte 
d’Ivoire or Cameroon. In the particular case of Cameroon, 
the situation of HAT is remarkable. Indeed, while 400.000 
persons were diagnosed and cured in 1930’s and 
campaigns of prophylaxy maintained until the 1960’s, no 
outbreak was noticed despite persistence of endemic foci 
and tsetse flies. This is surprising when comparing with 
the bordering countries such as Chad, Congo or Central 
African Republic where outbreaks are occurring in 
several foci since over 20 years. Such particular case of 
Cameroon must be investigated. 
Other new techniques have been very useful for 
studying vector behaviour. Indeed, MLEE allowed to 
distinguish human or non-human origin of tsetse blood 
meals (Diallo et al., 1997). This blood meals analysis was 
improved by Heteroduplex analysis, a PCR based 
method (Boakye et al., 1999). Thus, knowledge of 
contact between vectors and human or animal was 
improved, leading to a better understanding of the risk of 
transmission of HAT. This was confirmed by the 
identification of trypanosomes in vector (Masiga et al., 
1996). 
Some operational tools may improve HAT control, and 
new technologies allowed to explain some aspects of the 
epidemiology of HAT, through a better knowledge of the 
biology and taxonomy of trypanosomes. However, 
diagnosis is still based on parasite detection like in 
1930’s. It is urgent to improve tools for mass screening, 
diagnosis and stage determination for a field routine use. 
Furthermore, PCR based method protocols must be 





without trypanosomes isolation in vivo or in vitro. Thus, 
we may have a better identification of natural populations 
of parasites infecting patients (and animals), because 
mixed or co-infections should be evidenced. Studies on 
taxonomy, biology or drug sensitivity of T. b. gambiense 
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